Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

28.82
+0.09000.31%
Volume:2.57M
Turnover:74.57M
Market Cap:33.58B
PE:23.82
High:29.39
Open:28.93
Low:28.73
Close:28.73
52wk High:37.35
52wk Low:12.47
Shares:1.17B
Float Shares:1.14B
Volume Ratio:0.41
T/O Rate:0.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.21
EPS(LYR):1.21
ROE:20.79%
ROA:6.17%
PB:4.24
PE(LYR):23.82

Loading ...

Enphase, AST SpaceMobile, AppLovin, ConocoPhillips, Teva Shock

TIPRANKS
·
Mar 21

Barclays Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)

TIPRANKS
·
Mar 20

Top Teva Executive Makes Major Stock Move That Investors Can’t Ignore

TIPRANKS
·
Mar 20

A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Branded Drugs Pass $1b Quarterly Revenue

Simply Wall St.
·
Mar 17

J.P. Morgan Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

TIPRANKS
·
Mar 05

Teva Pharmaceuticals Price Target Raised to $41.00/Share From $40.00 by Piper Sandler

Dow Jones
·
Mar 04

Teva, Blackstone Life Sciences Enter $400 Million Funding Deal to Advance Duvakitug

MT Newswires Live
·
Mar 04

BRIEF-Teva Unveils Spring 2026 Collection “For Playground Earth” Evolves For Wherever Adventure Leads

Reuters
·
Mar 03

Teva Drug Updates Support Branded Growth Story And Valuation Upside Potential

Simply Wall St.
·
Mar 03

A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong 1 Year Shareholder Returns

Simply Wall St.
·
Mar 02

Stanley Druckenmiller says this is how he'd build a portfolio from scratch right now

Dow Jones
·
Feb 28

Has Teva (TEVA) Run Too Far After Its 102% One-Year Share Price Surge?

Simply Wall St.
·
Feb 24

FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application

Benzinga
·
Feb 23

Teva Pharmaceutical Says FDA Accepts New Drug Application for Olanzapine in Schizophrenia Treatment

MT Newswires Live
·
Feb 21

FDA accepts Teva NDA for olanzapine extended-release injectable suspension

TIPRANKS
·
Feb 21

BRIEF-Corcept Says US Court Rules Teva's Generic Korlym Does Not Infringe Corcept Patents

Reuters
·
Feb 20

Corcept Therapeutics Inc - Ruling Affirms December 2023 Verdict by Federal District Court

THOMSON REUTERS
·
Feb 20

Corcept Therapeutics Inc - Considering Judicial Review of Court Decision

THOMSON REUTERS
·
Feb 20

Corcept Provides Update on Patent Dispute With Teva Pharmaceuticals

THOMSON REUTERS
·
Feb 20

Truist Financial Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)

TIPRANKS
·
Feb 19